Synucleinopathies are a group of neurodegenerative disorders that include serious conditions such as Parkinson's disease and ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Cell-surface proteins are critical therapeutic targets and are vital to cellular communication, signaling, and homeostasis. However, developing high-affinity probes such as aptamers against these ...

Aptamer Group plc, the developer of novel Optimer ® binders to enable innovation in the life sciences industry, announces that it has opened its new facilities in York Science Park, UK, that will ...

Aptamer Group, the developer of diagnostic and therapeutic Optimer™ reagents, today announced that it has signed an agreement with the multinational pharmaceutical and biopharmaceutical company Takeda ...

Oligonucleotides are short, single strands of synthetic DNA or RNA. Although they are small, these molecules play an important role in molecular and synthetic biology applications. One type of ...

The AIM-listed biotechnology business expects to report revenue of approximately £1.5m for the year ended 30 June 2026, up ...

Generating specific cell lineages from induced pluripotent stem cells and embryonic stem cells is the holy grail of regenerative medicine. Guiding iPSCs toward a target cell line has garnered much ...

The U.S. Aptamers Market is projected to grow from USD 1.49 Billion in 2025 to USD 11.90 Billion by 2035, while Europe is ...